Inovio Pharmaceuticals
102 hedge funds and large institutions have $57.5M invested in Inovio Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 18 closing their positions.
1,161% more call options, than puts
Call options by funds: $2.02M | Put options by funds: $160K
19% more capital invested
Capital invested by funds: $48.4M → $57.5M (+$9.01M)
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
9.1% more ownership
Funds ownership: 38.97% → 48.07% (+9.1%)
3% more funds holding
Funds holding: 99 → 102 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.7M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$3.27M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.14M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.33M |
| 5 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.93M |
| 2 |
Morgan Stanley
New York
|
-$1.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.26M |
| 4 |
Millennium Management
New York
|
-$1.25M |
| 5 |
Renaissance Technologies
New York
|
-$580K |
INO Hedge Fund Activity: Q4 2025 in Review
102 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2025, worth a combined $57.5M — up 19% from $48.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new INO positions and 18 closed out — a net gain of 3 holders — while 25 added to existing stakes and 22 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $21.7M. The largest seller was Adage Capital Partners, cutting an estimated $1.93M.
- 102 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2025, up from 99 in Q3 2025.
- Funds reported $57.5M of Inovio Pharmaceuticals stock for Q4 2025, up 19% quarter-over-quarter.
- 21 funds opened new Inovio Pharmaceuticals positions in Q4 2025 and 18 closed out, a net change of +3 holders.
- The largest Inovio Pharmaceuticals buyer in Q4 2025 was Fidelity Investments, an estimated $21.7M added.
- The largest Inovio Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $1.93M sold.
Based on aggregated 13F filings for Q4 2025.